CD8A and neoplasm: Conversely, (partial) loss of HLA occurs in a sizeable fraction of NSCLC tumors, as well as HLA diversity modulate the prognostic impact of tumor-infiltrating CD8+ T cells, and thus survival after checkpoint blockade [8–11].